|F. Michael Ball|
Chief Executive Officer (CEO)
F. Michael (Mike) Ball, CEO, age 57, brings more than 25 years of healthcare experience to Hospira, the world's leading provider of injectable drugs and infusion technologies. Ball was appointed CEO and director in March 2011, succeeding the company's founding CEO, Christopher B. Begley.
Ball joined Hospira following a distinguished 16-year career with Allergan, Inc., a multi-specialty healthcare company, where he had served as its president since 2006 and previously held a number of leadership roles including executive vice president and president, Pharmaceuticals; president, North America region and president, Global Eyecare. During his tenure at Allergan, Ball was responsible for accelerating growth in international markets and leading the strategy and execution of global commercial activities for a diverse slate of businesses, including specialty pharmaceuticals, over-the-counter products and surgical devices.
Before Allergan, Ball served as senior vice president for Syntex Laboratories USA and president, Syntex Canada, where his responsibilities spanned marketing, sales, regulatory and clinical functions, as well as the creation of an authorized generics business. He started his healthcare career at Eli Lilly and Company.
Born in Canada, Ball earned both his bachelor's degree in life sciences and his master of business administration degree in marketing at Queen's University, Ontario, Canada. He completed an executive management program at Stanford University and serves on the board of KYTHERA Biopharmaceuticals, Inc.
Ball serves on the Science and Technology Committee.